Latest News
iBio, Inc.
- Pharos iBio Co., Ltd. Estimates – KRX:388870
- iBio Shareholders Approve Governance and Capital Structure Changes
- Form 4 Ibio Inc: David Arkowitz (Director) For: 14 October By Investing.com
- Bio’s Activin E Antibody IBIO-610 Shifts Semaglutide Weight Loss Toward Fat in Obese Primates
- iBio's IBIO-610 Achieves 93% Fat Loss in Eight-Week Obese NHP Study
- iBio - IBIO-610 Plus Semaglutide Preserves Lean Mass In Eight-Week Obese NHP Study
- iBio reports muscle preservation data for obesity drug candidate
- IBIO - EXPECTS TO START FIRST-IN-HUMAN TRIALS OF IBIO-610 IN FIRST HALF OF 2027
- iBio Highlights Data from a Non-human Primate Study
- iBio's IBIO-610 with semaglutide preserves musc...
- iBio, Inc. (IBIO) Presents at 2026 EASD Annual Meeting - Slideshow (NASDAQ:IBIO) 2026-10-07
- Ibio’s IBIO-610 reshapes weight loss composition
Headlines from the last 30 days, linking to the original publishers. See all market news →